The Use of Lumbar Erector Spinae Plane Block for Hip Arthroplasty at the L4 Interspace
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03801863 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 14, 2019
Last Update Posted : January 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Hip Arthropathy Regional Anesthesia | Procedure: Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375% Drug: Ropivacaine |
Hypothesis:
The erector spinae plane block will decrease opioid requirements in patients undergoing hip arthroplasty as compared to patients that do not receive the block.
Primary Objective:
To compare the opioid consumption in the post-anesthesia care unit (PACU) and at 24 hours postoperative (in morphine equivalents) in patients receiving regional anesthesia with spinal vs. spinal alone.
Secondary Endpoints:
To evaluate the pain scores at discharge from PACU, at 2 hours post PACU discharge, at 24 hours and at 48 hours postoperative; to evaluate the sensory distribution of the block (T10-L5); to evaluate whether or not patients that receive the block have evidence of quadricep muscle weakness
Design and methods This is a randomized, prospective study in patients receiving hip arthroplasty. Patients will be assigned to receive a lumbar erector spinae block versus no block. There will be no change in the primary anesthetic technique (spinal anesthesia with sedation) since these patients routinely get spinal anesthesia for hip arthroplasty. Consent for the study will be obtained in the preoperative area upon arrival for surgery. Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. Patients to receive a nerve block will receive mild sedation (1-2mg midazolam ± ≤100mcg fentanyl). All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
Postoperatively, the PACU nurse will be asked to document pain scores according to the Visual Analog Scale (VAS) and total dose of opioids given. The distribution of the sensory block and motor weakness will be documented in the anesthesiologist's PACU discharge note. For patients that receive the block, the Physical therapist note will be assessed for any report of quadriceps muscle weakness (i.e., evidence of buckling while walking).
For postoperative data collection, opioid consumption totals and the pain scores at 2 hours post admission, at 24 hours and 48 hours post-procedure will be collected from the electronic medical record (EMR) as documented by nurses on the admitting floor. Additionally, the Acute Pain service, who rounds on all patients that receive nerve blocks, will make a note of the pain scores of the patient and any residual muscle weakness or decreased sensation at 24- and 48-hours post-procedure. All data will then be extracted from the EMR by the research assistant.
| Study Type : | Observational |
| Estimated Enrollment : | 74 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | The Use of Lumbar Erector Spinae Plane Block for Hip Arthroplasty at the L4 Interspace- a Randomized Controlled Study Comparing the 24-hour Opioid Requirements. |
| Actual Study Start Date : | March 1, 2019 |
| Estimated Primary Completion Date : | December 1, 2022 |
| Estimated Study Completion Date : | December 24, 2022 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Ultrasound-guided Erector Spinae Block
Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
|
Procedure: Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%
Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used. Drug: Ropivacaine Using 0.375% Ropivacaine in the nerve block |
|
No Ultrasound-guided Erector Spinae Block
Patients with no peripheral nerve block to serve as the control.
|
- Opioid Consumption in PACU and 24 hours post surgery [ Time Frame: 24 hours ]To compare the opioid consumption in the post-anesthesia care unit (PACU) and at 24 hours postoperative (in morphine equivalents) in patients receiving regional anesthesia with spinal vs. spinal alone.
- Pain scores at 2 hours post PACU discharge [ Time Frame: 2 hours. Pain scores from 1 to 10. 10 being the worse pain and 1 being the least pain ]To evaluate the pain scores at 2 hours post PACU discharge
- To evaluate the sensory distribution of the block (T10-L5). [ Time Frame: 2 hours post-surgery ]Will test for temperature difference using ice cube.
- To evaluate whether or not patients that receive the block have evidence of quadricep muscle weakness [ Time Frame: 30 hours post-surgery ]Will have patient walk and Physical Therapist will assess for buckling of knee or potential falls while ambulating.
- Pain scores at 24 hours post PACU discharge [ Time Frame: 24 hours. Pain scores from 1 to 10. 10 being the worse pain and 1 being the least pain ]To evaluate the pain scores at 24 hours post PACU discharge
- Pain scores at 48 hours postoperative [ Time Frame: 48 hours post-surgery. Pain scores from 1 to 10. 10 being the worse pain and 1 being the least pain ]To evaluate the pain scores at 48 hours postoperative.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients undergoing primary hip arthroplasty
- ASA 1, 2, and 3
- Patients age ≥18 years
Exclusion Criteria:
- Patient refusal
- Inability to understand and sign consent
- Infection at the injection site
- Known allergy or hypersensitivity to ropivacaine or other amide local anesthetics
- Contraindication or patient refusal to get spinal anesthesia
- Thrombocytopenia (platelets < 100,000)
- Coagulopathy (INR > 1.4)
- Use of anticoagulant drugs that have not been discontinued in an appropriate amount of time before the surgery
- ASA 4 and 5
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03801863
| United States, New York | |
| Montefiore Medical Center- Wakefield Campus | |
| Bronx, New York, United States, 10467 | |
| Principal Investigator: | Iyabo Muse, MD | Montefiore Medical Center |
| Responsible Party: | Montefiore Medical Center |
| ClinicalTrials.gov Identifier: | NCT03801863 |
| Other Study ID Numbers: |
2018-9687 |
| First Posted: | January 14, 2019 Key Record Dates |
| Last Update Posted: | January 10, 2022 |
| Last Verified: | January 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Erector Spinae Plane Block Ropivacaine Ultrasound guided nerve block |
|
Joint Diseases Musculoskeletal Diseases Ropivacaine Anesthetics, Local Anesthetics |
Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |

